U.S. Markets closed

Aerpio Pharmaceuticals, Inc. (ARPO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.2000-0.0200 (-0.90%)
At close: 4:00PM EDT

Aerpio Pharmaceuticals, Inc.

9987 Carver Road
Suite 420
Cincinnati, OH 45242
United States
513 985 1920
http://www.aerpio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees12

Key Executives

NameTitlePayExercisedYear Born
Dr. Joseph H. GardnerFounder, Pres, Principal Exec. Officer & Director752.4kN/A1956
Ms. Regina MarekPrincipal Financial Officer, Principal Accounting Officer & VP of Fin.447.12kN/A1969
Mr. Kevin G. PetersChief Scientific Officer & Acting Chief Medical Officer625.96kN/A1957
Dr. Dhaval DesaiChief Strategy OfficerN/AN/A1978
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds that activate Tie2 for the treatment of ocular disease and vascular stabilization. The company's lead product candidate is razuprotafib, a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase , which has completed phase IIb clinical trial for the treatment of non-proliferative diabetic retinopathy, as well as has completed phase II clinical trial for the treatment of patients with open angle glaucoma/ocular hypertension. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications, including nephropathy and diabetic macular edema; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a licensing and collaboration agreement with Gossamer Bio, Inc. for the development and commercialization of GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed Phase 1b clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio.

Corporate Governance

Aerpio Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.